Seaward Management Limited Partnership decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 60,106 shares of the medical research company’s stock after selling 175 shares during the period. Seaward Management Limited Partnership’s holdings in Amgen were worth $9,145,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of AMGN. Bridges Investment Management Inc. increased its position in Amgen by 12.6% in the first quarter. Bridges Investment Management Inc. now owns 22,576 shares of the medical research company’s stock valued at $3,466,000 after buying an additional 2,531 shares during the last quarter. Windward Capital Management Co. CA increased its position in Amgen by 2.8% in the first quarter. Windward Capital Management Co. CA now owns 27,118 shares of the medical research company’s stock valued at $4,066,000 after buying an additional 738 shares during the last quarter. UMB Bank N A MO increased its position in Amgen by 6.4% in the first quarter. UMB Bank N A MO now owns 95,896 shares of the medical research company’s stock valued at $14,378,000 after buying an additional 5,740 shares during the last quarter. Raymond James Trust N.A. increased its position in Amgen by 59.9% in the first quarter. Raymond James Trust N.A. now owns 28,653 shares of the medical research company’s stock valued at $4,296,000 after buying an additional 10,739 shares during the last quarter. Finally, Narwhal Capital Management increased its position in Amgen by 2.5% in the first quarter. Narwhal Capital Management now owns 10,245 shares of the medical research company’s stock valued at $1,536,000 after buying an additional 250 shares during the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.
Shares of Amgen Inc. (NASDAQ:AMGN) traded up 0.82% during trading on Friday, hitting $166.81. The company had a trading volume of 3,999,620 shares. The stock’s 50-day moving average is $171.68 and its 200 day moving average is $161.02. The firm has a market capitalization of $124.83 billion, a P/E ratio of 17.07 and a beta of 0.87. Amgen Inc. has a 52-week low of $138.06 and a 52-week high of $176.85.
Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating the consensus estimate of $2.74 by $0.10. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. Amgen had a return on equity of 29.30% and a net margin of 33.07%. Amgen’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.57 earnings per share. Equities research analysts predict that Amgen Inc. will post $11.36 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Wednesday, August 17th were issued a $1.00 dividend. This represents a $4.00 annualized dividend and a yield of 2.40%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s dividend payout ratio (DPR) is presently 40.90%.
Several research analysts have commented on AMGN shares. Vetr downgraded Amgen from a “hold” rating to a “sell” rating and set a $166.35 price objective on the stock. in a report on Monday, August 1st. Goldman Sachs Group Inc. restated a “buy” rating and set a $204.00 price objective on shares of Amgen in a report on Thursday, September 8th. Cowen and Company reaffirmed a “buy” rating on shares of Amgen in a research report on Monday, September 19th. Jefferies Group reaffirmed a “buy” rating and set a $187.00 target price on shares of Amgen in a research report on Wednesday, July 13th. Finally, Piper Jaffray Cos. reaffirmed a “buy” rating and set a $193.00 target price on shares of Amgen in a research report on Thursday, July 28th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $185.06.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.20% of the stock is owned by corporate insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.